000			01712 a2200433 4500
005			20250516072157.0
264		0	_c20120515
008			201205s 0 0 eng d
022			_a1478-3231
024	7		_a10.1111/j.1478-3231.2011.02719.x _2doi
040			_aNLM _beng _cNLM
100	1		_aSulkowski, Mark S
245	0	0	_aHepatitis C virus-human immunodeficiency virus coinfection. _h[electronic resource]
260			_bLiver international : official journal of the International Association for the Study of the Liver _cFeb 2012
300			_a129-34 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAntiviral Agents _xtherapeutic use
650	0	4	_aCoinfection _xdrug therapy
650	0	4	_aDrug Interactions
650	0	4	_aDrug Therapy, Combination
650	0	4	_aHIV Infections _xcomplications
650	0	4	_aHepatitis C, Chronic _xcomplications
650	0	4	_aHumans
650	0	4	_aInterferon alpha-2
650	0	4	_aInterferon-alpha _xtherapeutic use
650	0	4	_aMale
650	0	4	_aOligopeptides _xadverse effects
650	0	4	_aPatient Selection
650	0	4	_aPolyethylene Glycols _xtherapeutic use
650	0	4	_aProline _xadverse effects
650	0	4	_aRecombinant Proteins _xtherapeutic use
650	0	4	_aRibavirin _xtherapeutic use
650	0	4	_aSerine Proteinase Inhibitors _xadverse effects
650	0	4	_aTreatment Failure
650	0	4	_aTreatment Outcome
650	0	4	_aViral Load _xdrug effects
773	0		_tLiver international : official journal of the International Association for the Study of the Liver _gvol. 32 Suppl 1 _gp. 129-34
856	4	0	_uhttps://doi.org/10.1111/j.1478-3231.2011.02719.x _zAvailable from publisher's website
999			_c21431016 _d21431016